What peptide-based topical agents and protocols are recommended for wound healing in adult patients with acute or chronic skin ulcers, including diabetic foot ulcers, pressure injuries, or venous ulcers?

Wound Healing and Peptides

Do not use peptide-based topical agents or growth factor therapies as routine adjunctive treatments for wound healing in diabetic foot ulcers or other chronic wounds, as current high-quality guidelines recommend against their use based on insufficient evidence of clinical benefit.

Evidence-Based Recommendations

The most recent and authoritative guidance comes from the 2024 IWGDF (International Working Group on the Diabetic Foot) guidelines, which provide clear direction on peptide and growth factor therapies 1:

Growth Factor Therapy (Including Peptides)

• We suggest not using growth factor therapy as an adjunct therapy to standard of care for wound healing in people with diabetes-related foot ulcers (Conditional; Low quality evidence) 1
• This recommendation specifically addresses peptide-based growth factors like PDGF (becaplermin), which despite earlier promise, lacks strong confirmatory evidence 2

What IS Recommended Instead

Standard of care remains the foundation:

• Sharp debridement performed by clinicians based on clinical need 1
• Basic wound dressings that absorb exudate and maintain moist wound environment 1
• Appropriate offloading to minimize trauma 1
• Treatment of infection when present 2
• Revascularization if appropriate and feasible 2

Limited Exceptions Where Peptide-Related Products May Be Considered

Only after standard care has failed and resources exist:

1. Autologous leucocyte, platelet, and fibrin patch - Consider use for diabetic foot ulcers when best standard care alone has been ineffective and where resources/expertise exist for regular venepuncture (Conditional; Moderate quality evidence) 1

2. Placental-derived products - Consider as adjunct when standard care alone has failed (Conditional; Low quality evidence) 1

3. Sucrose-octasulfate impregnated dressing - Consider for non-infected, neuro-ischemic diabetic foot ulcers with insufficient healing after ≥2 weeks of best standard care including offloading (Conditional; Moderate quality evidence) 1

Clinical Algorithm for Decision-Making

Step 1: Implement Standard Care First

• Sharp debridement
• Moisture-balancing dressings (not antimicrobial, not collagen, not alginate) 1
• Offloading
• Infection control if needed
• Vascular assessment

Step 2: Assess Response at 2 Weeks

• If healing progresses → continue standard care
• If insufficient healing → proceed to Step 3

Step 3: Consider Limited Adjunctive Options (Only if resources available)

• For neuro-ischemic diabetic foot ulcers: Sucrose-octasulfate dressing 1
• If venepuncture capability exists: Autologous leucocyte/platelet/fibrin patch 1
• As last resort: Placental-derived products 1

Step 4: What NOT to Use

• Topical growth factors (including becaplermin/PDGF) 1
• Collagen dressings 1
• Antimicrobial peptide dressings 1
• Honey or bee-related products 1
• Herbal remedies 1

Important Caveats and Pitfalls

Common Misconceptions to Avoid

1. "Newer is better" fallacy: Despite emerging research on antimicrobial peptides showing promise in laboratory settings 3, 4, 5, these have not translated to guideline-level recommendations for clinical practice

2. Pressure ulcers differ from diabetic ulcers: The 2015 ACP guidelines for pressure ulcers showed low-quality evidence for PDGF benefit 6, but this does not extend to diabetic foot ulcers where evidence is even weaker

3. Research vs. clinical reality: While recent studies (2025-2026) describe peptide-ionic liquid conjugates 4, peptide-loaded nanoparticles 7, and smart delivery systems 3, 8, these remain investigational and are not ready for routine clinical application

Why Guidelines Recommend Against Peptide Therapies

The IWGDF systematically reviewed evidence and found:

• Insufficient clinical benefit to justify routine use
• Cost-effectiveness not established 2
• Quality of evidence remains low despite improvements 1
• Standard care alone is often adequate when properly implemented

Special Populations

For pressure ulcers (non-diabetic): The evidence is similarly weak, with 2015 ACP guidelines showing only low-quality evidence for PDGF and mixed findings for other interventions 6

For venous ulcers: No specific peptide-based recommendations exist in the provided guidelines; standard wound care principles apply

The Bottom Line

Focus clinical efforts on optimizing standard care rather than seeking peptide-based solutions. The evidence consistently shows that proper debridement, appropriate dressings, offloading, and addressing underlying pathology (infection, ischemia) remain more important than any adjunctive peptide therapy. Only consider the limited exceptions (autologous platelet products, placental-derived products, or sucrose-octasulfate dressings) after documented failure of best standard care for at least 2 weeks, and only where institutional resources and expertise support their use 1.